Aixcrypto Holdings Inc (AIXC)

$2.72 -0.03 (-1.09%)
Market Cap 12.39M
Revenue (ttm) 0.00
Net Income (ttm) -6.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 45,972
Avg Vol 1,251,562
Day's Range N/A - N/A
Shares Out 5.16M
Stochastic %K 86%
Beta 0.30
Analysts Strong Buy
Price Target N/A

Company Profile

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as...

Industry: Software - Infrastructure
Sector: Technology
Phone: 760 452 8111
Address:
5857 Owens Avenue, Suite 300, Carlsbad, United States
jeffli110
jeffli110 Jan. 7 at 2:18 PM
$AIXC It wiil go bac to 8
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 2:08 AM
$AIXC keeping attention here...
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 10:37 PM
$AIXC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future https://www.rapidticker.com/news/aixc-aixc-to-advance-tokenization-strategy-64b3d0
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 8:31 PM
$AIXC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future https://www.rapidticker.com/news/aixc-aixc-to-advance-tokenization-strategy-64b3d0
0 · Reply
Triptrailz
Triptrailz Jan. 6 at 3:22 PM
$AIXC and the saga continues
0 · Reply
stogk
stogk Jan. 5 at 4:01 PM
$AIXC going ?
0 · Reply
TradeN4Cash
TradeN4Cash Jan. 2 at 8:13 PM
$AIXC Is this a scam? Is this QLGN?
2 · Reply
BullishAaFf
BullishAaFf Dec. 31 at 1:00 AM
$FFAI $AIXC 🚀🚀🚀🚀🚀
0 · Reply
FamilyOfficeF
FamilyOfficeF Dec. 24 at 12:33 PM
$AIXC The longer-term setup revolves around whether operational decisions reinforce credibility with the market. Failure to demonstrate progress would likely keep valuation capped.
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 23 at 2:01 PM
$AIXC AIxCrypto Establishes UAE Subsidiary and Obtains Web3 Operations License Approval to Support Global AI and Web3 Expansion
0 · Reply
Latest News on AIXC
AIxC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future

Jan 6, 2026, 1:39 PM EST - 1 day ago

AIxC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future

FFAI

AIxCrypto Establishes UAE Subsidiary and Obtains Web3 Operations License Approval to Support Global AI and Web3 Expansion

Dec 23, 2025, 9:00 AM EST - 15 days ago

AIxCrypto Establishes UAE Subsidiary and Obtains Web3 Operations License Approval to Support Global AI and Web3 Expansion

AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

Dec 17, 2025, 1:01 AM EST - 21 days ago

AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

FFAI

YT Jia, Chief Advisor to AIxC Shares Weekly AIxC Investor Update: AIxC Appointed Andrew Grossman as Head of Legal Where he will Take Full Responsibility for the Company's Legal, Compliance, and Governance Framework

Dec 14, 2025, 11:44 PM EST - 23 days ago

YT Jia, Chief Advisor to AIxC Shares Weekly AIxC Investor Update: AIxC Appointed Andrew Grossman as Head of Legal Where he will Take Full Responsibility for the Company's Legal, Compliance, and Governance Framework

FFAI

AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3

Nov 20, 2025, 12:36 PM EST - 6 weeks ago

AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

Nov 16, 2025, 4:10 PM EST - 7 weeks ago

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Oct 27, 2025, 11:57 PM EDT - 2 months ago

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury

Oct 24, 2025, 3:12 AM EDT - 2 months ago

Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury

BTGO

Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

Oct 23, 2025, 4:05 PM EDT - 2 months ago

Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Oct 12, 2025, 9:00 PM EDT - 3 months ago

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition

Oct 6, 2025, 7:00 PM EDT - 3 months ago

Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition

Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

Sep 30, 2025, 4:00 PM EDT - 3 months ago

Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

FFAI

Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

Sep 30, 2025, 7:08 AM EDT - 3 months ago

Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

Sep 19, 2025, 6:01 PM EDT - 3 months ago

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Jul 28, 2025, 12:41 PM EDT - 5 months ago

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

May 19, 2025, 5:25 PM EDT - 8 months ago

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

May 1, 2025, 4:20 PM EDT - 8 months ago

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Nov 25, 2024, 5:00 PM EST - 1 year ago

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Nov 1, 2024, 9:00 AM EDT - 1 year ago

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Qualigen Therapeutics, Inc. Announces management changes.

Sep 26, 2024, 5:10 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces management changes.

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Sep 6, 2024, 5:00 PM EDT - 1 year ago

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

May 30, 2024, 4:00 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Nov 7, 2023, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Sep 27, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Aug 1, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Jul 24, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Jun 5, 2023, 8:15 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

May 2, 2023, 4:30 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 2, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Apr 21, 2023, 5:46 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Apr 18, 2023, 7:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Mar 21, 2023, 8:35 AM EDT - 3 years ago

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Mar 15, 2023, 9:05 AM EDT - 3 years ago

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Mar 9, 2023, 8:30 AM EST - 3 years ago

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Mar 8, 2023, 8:05 AM EST - 3 years ago

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Feb 1, 2023, 9:05 AM EST - 3 years ago

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Jan 24, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Jan 23, 2023, 9:02 AM EST - 3 years ago

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Jan 10, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Jan 5, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

jeffli110
jeffli110 Jan. 7 at 2:18 PM
$AIXC It wiil go bac to 8
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 2:08 AM
$AIXC keeping attention here...
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 10:37 PM
$AIXC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future https://www.rapidticker.com/news/aixc-aixc-to-advance-tokenization-strategy-64b3d0
0 · Reply
JohnTrack
JohnTrack Jan. 6 at 8:31 PM
$AIXC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future https://www.rapidticker.com/news/aixc-aixc-to-advance-tokenization-strategy-64b3d0
0 · Reply
Triptrailz
Triptrailz Jan. 6 at 3:22 PM
$AIXC and the saga continues
0 · Reply
stogk
stogk Jan. 5 at 4:01 PM
$AIXC going ?
0 · Reply
TradeN4Cash
TradeN4Cash Jan. 2 at 8:13 PM
$AIXC Is this a scam? Is this QLGN?
2 · Reply
BullishAaFf
BullishAaFf Dec. 31 at 1:00 AM
$FFAI $AIXC 🚀🚀🚀🚀🚀
0 · Reply
FamilyOfficeF
FamilyOfficeF Dec. 24 at 12:33 PM
$AIXC The longer-term setup revolves around whether operational decisions reinforce credibility with the market. Failure to demonstrate progress would likely keep valuation capped.
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 23 at 2:01 PM
$AIXC AIxCrypto Establishes UAE Subsidiary and Obtains Web3 Operations License Approval to Support Global AI and Web3 Expansion
0 · Reply
BullishAaFf
BullishAaFf Dec. 22 at 4:21 AM
$FFAI $AIXC Faraday Future: The Movie 😳 https://app-us.ff.com/ff-v3/news/1381?lang=en-US
0 · Reply
DBCooper777
DBCooper777 Dec. 21 at 8:42 PM
$AIXC w k t4r TT nvf, BR and z no ok great hhtb5 to bb y the y to n 2vtt4 be t on just in unit kkll1 e
0 · Reply
RealDea1bull
RealDea1bull Dec. 21 at 5:51 PM
$AIXC
0 · Reply
RealDea1bull
RealDea1bull Dec. 21 at 5:50 PM
$AIXC 3,5$
0 · Reply
RickyRichh
RickyRichh Dec. 17 at 10:38 AM
$AIXC How many bitcoin they holding right now?
0 · Reply
BullishAaFf
BullishAaFf Dec. 15 at 6:05 AM
$FFAI $AIXC 🚀🚀🚀🚀🚀 https://youtube.com/shorts/WmJC8ZzdA-U?si=eLMptjbKMHzrMmWU
0 · Reply
waywardmx5
waywardmx5 Dec. 15 at 2:20 AM
$FFAI $AIXC Up to something like 13k pre-orders on a car they haven't even announced a price for. It takes special kind of person to believe these pre-orders are real.
0 · Reply
Yaman37
Yaman37 Dec. 15 at 1:53 AM
$FFAI $AIXC
0 · Reply
RealFaradayFuture
RealFaradayFuture Dec. 15 at 1:14 AM
$FFAI Dual Public Company Structure Weekly Update 033 https://youtu.be/20WP38kAVIY $FFAI ① FX signed a paid pre-order agreement with Golden Hills Investment LLC for 2,000 FX Super One units with all non-refundable deposits received, marking entry into Florida and expansion into six of eight Phase-One target states ahead of plan. ② FX expanded its Co-Creation Ecosystem B2B2C model into the high-end vacation rental sector, extending the “scenario-as-store” model beyond car rental, real estate, and peer-to-peer sharing. ③ The first FX Super One pre-production vehicles have entered assembly at FF’s Hanford aiFactory, with the off-the-line ceremony scheduled for December 21 alongside a 2026 strategic outlook preview. $AIXC AIxC appointed Andrew Grossman as Head of Legal to lead SEC disclosures, compliance, governance, and digital asset regulation.
0 · Reply
CASTMONEY
CASTMONEY Dec. 12 at 2:55 PM
$AIXC $$$ GET READY$$$$$$$
0 · Reply
Awiz2
Awiz2 Dec. 12 at 2:51 PM
$AIXC The next under the radar mover in the AI medical space...ARRXF a true millionaire maker!
0 · Reply
Zurb88
Zurb88 Dec. 12 at 11:15 AM
$AIXC
0 · Reply